TEL AVIV, Israel, Aug. 21, 2020 /PRNewswire/ -- Therapix
Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty,
clinical-stage pharmaceutical company focusing on the development
of cannabinoid-based treatments, announced today the replacement of
its board of directors. The Company's new six-member board of
directors will include Itschak
Shrem, Amitay Weiss, Moshe
Revach, Lior Amit, Lior Vider and Liat
Sidi.
Itschak Shrem was appointed as
Chairman of the new board of directors, and Amitay Weiss, in addition to his membership with
the board, will assume the position of Chief Executive Officer of
the Company.
"I'm pleased to accept the responsibility of, and look forward
to, leading the Company in a new and exciting direction," said Mr.
Itschak Shrem, the Company's new
Chairman of the board of directors. "Under new leadership, I'm
confident the Company will finally maximize its impressive
potential and, at the same time, deliver a deserving return to our
shareholders," he continued.
Itschak Shrem has
more than 40 years of experience in financial markets and venture
capital. In 1991, Mr. Shrem founded Dovrat Shrem Ltd., an
investment banking, management and technology company. Prior to
that, he spent 15 years at Clal Israel Ltd., where he served in
various capacities, including chief operating officer, and was
responsible for capital markets and insurance businesses. In 1993,
Mr. Shrem founded Pitango Venture Capital Fund (formerly, Polaris)
and served as a partner of Pitango Funds I, II and III. He has been
the Managing Director of Yaad Consulting 1995 Ltd. since 1995. Mr.
Shrem currently serves on the board of directors of Rail Visions
Ltd. Previously, Mr. Shrem served on the board of Tel-Aviv Sourasky
Medical Center, the Weizman Institute Eden Spring Ltd., Nano
Dimension Ltd., Ormat Industries Ltd., Retalix Ltd. and as chairman
of Sphera Funds Management Ltd. Mr. Shrem holds a B.A in Economics
and Accounting from Bar-Ilan University
and an M.B.A. from Tel-Aviv
University.
Amitay Weiss currently
serves as chairman of the board of directors of P.L.T Financial
Services Ltd., as chairman of the board of directors of Matomy
Media Group Ltd. and as an external director of Cofix Group Ltd. In
2016, Mr. Weiss founded Amitay Wiss Management Ltd. and now serves
as its chief executive officer. From 2001 until 2015, Mr. Weiss
served as vice president of business marketing & development
and in various other positions at Bank Poalei Agudat Israel Ltd.
(PAGI) from the First International Bank of Israel group. Mr. Weiss holds a B.A in
economics from New Engand College, M.B.A. in business
administration from Ono Academic College in Israel, an Israeli branch of University of
Manchester and LL.B from the Ono Academic College.
Lior
Amit serves as a consultant to both private
and public companies as well as individuals. Mr. Amit serves as
director of ScoutCam Inc., Matomy Ltd., Nirplex Ltd., Ronimar Ltd.,
Endemol Israel Ltd. and B.S.S.CH. - The Israeli Credit Insurance
Company Ltd. Mr. Amit previously served as chief financial officer
for BBR Saatchi & Saatchi Group from 1996 to 2013. Mr. Amit is
an Israeli Certified Public Accountant. Mr. Amit holds a B.A in
economics and accounting and M.B.A. in insurance and finance from
Tel-Aviv University.
Lior Vider serves as
a senior investment portfolio manager at Epsilon Investment House
Ltd. since 2010. Mr. Vider previously served as chief investment
manager for Impact Investment Management Ltd., from the Union Bank
group from 2007 to 2010 and as chairman of the board of directors
and member of the group's investment committee of Rahkia Capital
Markets Ltd. from 2006 to 2007. Mr. Vider also served as manager of
the financial desk and as a trader in trust funds of Ilanot
Discount from 2003 to 2006. Mr. Vider founded and managed
sponser.co.il, a financial portal specializing in services for
investors from 2005 to 2017. Mr. Vider holds a B.A in industry and
management engineering from Shenkar
College in Israel.
Moshe Revach serves as deputy mayor of the city of
Ramat Gan, Israel, has held both
the sports and government relations portfolios in the Ramat Gan
municipality since 2013, and has served in various other Ramat Gan
municipality positions since 2008. Mr. Revach serves as a director
of L.L.N IT solutions, a wholly-owned subsidiary of the Jewish
Agency for Israel and of Biomedico
Hadarim Ltd. Mr. Revach previously served as a director of the RPG
Economic Society and Jewish Experience Company on behalf of the
Jewish Agency. Mr. Revach holds an LL.B from the Ono Academic
College, Israel, and B.A in
management and economics from the University of Derby.
Liat Sidi serves as the
manager of the accounting department for Foresight Autonomous
Holdings Ltd. Ms. Sidi previously served as an accountant for
Panaxia Labs Israel Ltd. from 2015 to 2020 and as an accountant for
Soho Real Estate Ltd. from 2015 to 2016. Ms. Sidi also served as an
accountant for Feldman-Felco Ltd. from 2006 to 2010 and as an
accountant for Eli Abraham
accounting firm from 2000 to 2006. Ms. Sidi completed tax, finance
and accounting studies in Ramat Gan
College of Accounting.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, the Company is using forward-looking
statements when it discusses the successful performance of the
Company under its new leadership. Because such statements deal with
future events and are based on the Company's current expectations,
they are subject to various risks and uncertainties and actual
results, performance or achievements of the Company could differ
materially from those described in or implied by the statements in
this press release. The forward-looking statements contained or
implied in this press release are subject to other risks and
uncertainties, including those discussed under the heading "Risk
Factors" the Company's Annual Report on Form 20-F filed with the
SEC on June 15, 2020, and in
subsequent filings with the U.S. Securities and Exchange
Commission. Except as otherwise required by law, the Company
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events or
circumstances or otherwise.
About Therapix Biosciences (OTC Pink: TRPXY):
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in the following drug development programs based on
tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol
(CBD): THX-110 for the treatment of Tourette syndrome and for the
treatment of obstructive sleep apnea; THX-160 for the treatment of
pain; and THX-210 for the treatment of autism spectrum
disorder and epilepsy. Please visit our website for more
information at www.therapixbio.com, the content of which is
not a part of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/therapix-biosciences-announces-replacement-of-its-board-of-directors-301116296.html
SOURCE Therapix Biosciences Ltd.